Livzon Pharmaceutical Group Inc.

SEHK:1513 Stock Report

Market Cap: HK$32.1b

Livzon Pharmaceutical Group Past Earnings Performance

Past criteria checks 3/6

Livzon Pharmaceutical Group has been growing earnings at an average annual rate of 8%, while the Pharmaceuticals industry saw earnings growing at 5.7% annually. Revenues have been growing at an average rate of 5.9% per year. Livzon Pharmaceutical Group's return on equity is 14.9%, and it has net margins of 17.1%.

Key information

8.0%

Earnings growth rate

8.2%

EPS growth rate

Pharmaceuticals Industry Growth5.6%
Revenue growth rate5.9%
Return on equity14.9%
Net Margin17.1%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Livzon Pharmaceutical Group makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SEHK:1513 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2411,8572,0253,8771,083
30 Jun 2412,0221,9904,0401,215
31 Mar 2412,2601,9804,2151,261
31 Dec 2312,4301,9544,2681,335
30 Sep 2312,7962,0044,4041,434
30 Jun 2313,0172,0264,5901,483
31 Mar 2312,5641,9384,3731,450
31 Dec 2212,6301,9094,5501,427
30 Sep 2212,1831,8304,4381,338
30 Jun 2212,1311,7314,4731,193
31 Mar 2212,1931,8094,5521,203
01 Jan 2212,0641,7764,5561,146
30 Sep 2111,9641,7464,5501,086
30 Jun 2111,6611,7734,3681,085
31 Mar 2111,3651,8354,117982
01 Jan 2110,5201,7153,740884
30 Sep 2010,0151,6853,530835
30 Jun 209,5411,5693,382751
31 Mar 209,2821,3093,588728
01 Jan 209,3851,3033,728733
30 Sep 199,3141,1823,853681
30 Jun 199,2351,1883,938593
31 Mar 199,0991,1283,824578
31 Dec 188,8611,0823,782549
30 Sep 188,8511,1233,722494
30 Jun 188,8214,5583,744500
31 Mar 188,7744,5013,756536
01 Jan 188,5314,4293,767427
30 Sep 178,4504,4163,955283
30 Jun 178,1428793,903172
31 Mar 178,0328294,0150
31 Dec 167,6527843,8140
30 Sep 167,4587423,6240
30 Jun 167,2896913,5310
31 Mar 166,8136703,2500
31 Dec 156,6216233,1400
30 Sep 156,3115883,0310
30 Jun 156,0315662,8990
31 Mar 155,8695552,8380
31 Dec 145,5445162,6580
30 Sep 145,5065322,6290
30 Jun 145,0855192,4530
31 Mar 144,7914842,3190
31 Dec 134,6194882,2520

Quality Earnings: 1513 has high quality earnings.

Growing Profit Margin: 1513's current net profit margins (17.1%) are higher than last year (15.7%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 1513's earnings have grown by 8% per year over the past 5 years.

Accelerating Growth: 1513's earnings growth over the past year (1%) is below its 5-year average (8% per year).

Earnings vs Industry: 1513 earnings growth over the past year (1%) did not outperform the Pharmaceuticals industry 9.4%.


Return on Equity

High ROE: 1513's Return on Equity (14.9%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies